Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) have received a consensus recommendation of “Moderate Buy” from the eight ratings firms that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $3.3333.

Several research firms recently weighed in on RVPH. HC Wainwright reissued a “buy” rating and set a $4.00 price target on shares of Reviva Pharmaceuticals in a report on Tuesday, December 23rd. Chardan Capital reiterated a “buy” rating and set a $2.00 price objective on shares of Reviva Pharmaceuticals in a research report on Monday, January 5th. Wall Street Zen raised shares of Reviva Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, December 27th. D. Boral Capital restated a “buy” rating and issued a $2.00 price target on shares of Reviva Pharmaceuticals in a research note on Tuesday, December 23rd. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a research note on Thursday, January 22nd.

Reviva Pharmaceuticals Stock Down 0.2%

Reviva Pharmaceuticals stock opened at $0.25 on Friday. The company’s 50-day moving average price is $0.35 and its two-hundred day moving average price is $0.46. The stock has a market cap of $29.28 million, a P/E ratio of -0.55 and a beta of 0.06. Reviva Pharmaceuticals has a twelve month low of $0.25 and a twelve month high of $1.70.

Hedge Funds Weigh In On Reviva Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the stock. NewEdge Advisors LLC bought a new stake in shares of Reviva Pharmaceuticals during the 1st quarter valued at $58,000. XTX Topco Ltd bought a new position in shares of Reviva Pharmaceuticals in the second quarter worth $31,000. Lido Advisors LLC acquired a new position in Reviva Pharmaceuticals in the third quarter valued at about $37,000. State Street Corp lifted its position in Reviva Pharmaceuticals by 202.4% during the fourth quarter. State Street Corp now owns 383,200 shares of the company’s stock worth $107,000 after purchasing an additional 256,500 shares during the period. Finally, Geode Capital Management LLC grew its stake in Reviva Pharmaceuticals by 6.9% during the second quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock worth $171,000 after buying an additional 29,063 shares in the last quarter. Institutional investors own 63.18% of the company’s stock.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.